Literature DB >> 21253682

[Diagnostic evaluation of lung cancer].

F J F Herth1, C-P Heussel.   

Abstract

Lung cancer is the fourth rate cause of death in Germany. Symptoms are mainly unspecific and develop lately. Clinical history and examination come in first place of the diagnostic procedure. X-ray of the thorax is the basis of imaging and is completed by a CT scan of the chest. Afterwards, a biopsy for histological or cytological evaluation should be performed by the least invasive method, mostly bronchoscopy. Supplemented by modern techniques as narrow-band-imaging, endobronchial ultrasound and electromagnetic navigation, bronchoscopy takes a high value in the diagnostic procedure. Further staging is performed depending upon individual therapeutic options. Positron-emission-tomography has good evidence in lung cancer. On the one hand it serves for further evaluation of mediastinal lymphadenopathy and on the other it can complete extrathoracical staging. This should comprise the most prevalent localizations of metastasis, the adrenal glands, liver, and bones, while especially the brain should be imaged with usage of magnet resonance imaging.

Entities:  

Mesh:

Year:  2011        PMID: 21253682     DOI: 10.1007/s00108-010-2697-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

1.  Electromagnetic navigation diagnostic bronchoscopy in peripheral lung lesions.

Authors:  Ralf Eberhardt; Devanand Anantham; Felix Herth; David Feller-Kopman; Armin Ernst
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

2.  Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes.

Authors:  F J F Herth; R Eberhardt; P Vilmann; M Krasnik; A Ernst
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

3.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

4.  Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition).

Authors:  Stephen G Spiro; Michael K Gould; Gene L Colice
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

5.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition).

Authors:  Gerard A Silvestri; Michael K Gould; Mitchell L Margolis; Lynn T Tanoue; Douglas McCrory; Eric Toloza; Frank Detterbeck
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

6.  Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  M Patricia Rivera; Atul C Mehta
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

7.  The clinical evaluation for detecting metastatic lung cancer. A meta-analysis.

Authors:  G A Silvestri; B Littenberg; G L Colice
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

8.  Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma.

Authors:  P Kormas; J R Bradshaw; K Jeyasingham
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

9.  Ultrasound vs. CT in detecting chest wall invasion by tumor: a prospective study.

Authors:  Venkata Bandi; William Lunn; Armin Ernst; Ralf Eberhardt; Hans Hoffmann; Felix J F Herth
Journal:  Chest       Date:  2007-10-20       Impact factor: 9.410

10.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.